453 related articles for article (PubMed ID: 29309058)
21. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
Lei Q; Jiao J; Xin L; Chang CJ; Wang S; Gao J; Gleave ME; Witte ON; Liu X; Wu H
Cancer Cell; 2006 May; 9(5):367-78. PubMed ID: 16697957
[TBL] [Abstract][Full Text] [Related]
22. Mouse models in tumor suppression.
Ghebranious N; Donehower LA
Oncogene; 1998 Dec; 17(25):3385-400. PubMed ID: 9917000
[TBL] [Abstract][Full Text] [Related]
23. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
[TBL] [Abstract][Full Text] [Related]
24. The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer.
Kazantseva M; Mehta S; Eiholzer RA; Gimenez G; Bowie S; Campbell H; Reily-Bell AL; Roth I; Ray S; Drummond CJ; Reid G; Joruiz SM; Wiles A; Morrin HR; Reader KL; Hung NA; Baird MA; Slatter TL; Braithwaite AW
Cell Death Dis; 2019 Aug; 10(9):631. PubMed ID: 31431617
[TBL] [Abstract][Full Text] [Related]
25. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
26. Epigallocatechin-3-gallate promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells via PTEN.
Yao S; Zhong L; Chen M; Zhao Y; Li L; Liu L; Xu T; Xiao C; Gan L; Shan Z; Liu B
Int J Oncol; 2017 Sep; 51(3):899-906. PubMed ID: 28766684
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression.
Rodriguez M; Siwko S; Zeng L; Li J; Yi Z; Liu M
Oncogene; 2016 Mar; 35(9):1153-62. PubMed ID: 26028029
[TBL] [Abstract][Full Text] [Related]
28. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
[TBL] [Abstract][Full Text] [Related]
29. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
30. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis.
Kim MJ; Cardiff RD; Desai N; Banach-Petrosky WA; Parsons R; Shen MM; Abate-Shen C
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2884-9. PubMed ID: 11854455
[TBL] [Abstract][Full Text] [Related]
31. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
Hill R; Song Y; Cardiff RD; Van Dyke T
Cancer Res; 2005 Nov; 65(22):10243-54. PubMed ID: 16288012
[TBL] [Abstract][Full Text] [Related]
33. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
34. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.
Duechler M; Peczek L; Zuk K; Zalesna I; Jeziorski A; Czyz M
Immunobiology; 2014 Feb; 219(2):158-65. PubMed ID: 24091277
[TBL] [Abstract][Full Text] [Related]
35. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.
Salnikow K; Costa M; Figg WD; Blagosklonny MV
Cancer Res; 2000 Oct; 60(20):5630-4. PubMed ID: 11059752
[TBL] [Abstract][Full Text] [Related]
36. Pten dose dictates cancer progression in the prostate.
Trotman LC; Niki M; Dotan ZA; Koutcher JA; Di Cristofano A; Xiao A; Khoo AS; Roy-Burman P; Greenberg NM; Van Dyke T; Cordon-Cardo C; Pandolfi PP
PLoS Biol; 2003 Dec; 1(3):E59. PubMed ID: 14691534
[TBL] [Abstract][Full Text] [Related]
37. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
[TBL] [Abstract][Full Text] [Related]
38. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
[TBL] [Abstract][Full Text] [Related]
39. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
[TBL] [Abstract][Full Text] [Related]
40. PTENα functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer.
Sun Y; Lu D; Yin Y; Song J; Liu Y; Hao W; Qi F; Zhang G; Zhang X; Liu L; Lin Z; Liang H; Zhao X; Jin Y; Yin Y
Nat Commun; 2021 Aug; 12(1):5147. PubMed ID: 34446716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
